Manufacturer's ref.No: (b)(4).No device was received for analysis at the time of submission of the initial 3500a.Since the product was not returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because the lot number was provided by the customer.Biosense webster manufacturer's report numbers: 2029046-2020-01318, 2029046-2020-01319.Are related to the same incident.
|
This complaint is from a literature source.The following complications were reported in this publication: it was reported that 2 patients underwent catheter ablation of atrial fibrillation and suffered femoral artery pseudoaneurysm.Intervention was required puncture, suction and compression.Model and catalog number are not available, but the suspected device is thermocool smarttouch® catheter.Other biosense webster devices that were also used in this study: carto 3, pentaray catheter, carto visitag¿ module non-biosense webster devices that were also used in this study: none publication details: title: single transseptal puncture technique and contact force catheter: a simplified ablation strategy for paroxysmal atrial fibrillation objective: the present study aimed to evaluate the safety and efficacy of an optimized single transseptal puncture technique and contact force sensing atrial fibrillation (af) radiofrequency catheter ablation (rfca) strategy within a clinical setting.Methods: fast anatomic mapping and contact force sensing ablation was applied to patients with paroxysmal af (paf) ablation between september 2014 and december 2016 using a single trans-septal sheath.Pulmonary vein isolation (pvi) and linear ablation were performed in paf individually with a 10-20 g contact force with minimal fluoroscopy.Stimulation with 10 ma outputs on the lesions without capture was used as endpoint.A total of 419 consecutive patients who underwent first-time rfca were enrolled in the current study, and acute pvi was achieved in all patients.
|